THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Clinical trial NCT00448279 · COMPLETED
Trial details
- NCT number
- NCT00448279
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-04-01
- Primary completion
- 2010-09-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.